Agenus Inc. (NASDAQ:AGEN) Short Interest Down 6.4% in November

Agenus Inc. (NASDAQ:AGEN) was the target of a large drop in short interest during the month of November. As of November 15th, there was short interest totalling 2,620,000 shares, a drop of 6.4% from the October 31st total of 2,800,000 shares. Based on an average daily trading volume, of 452,300 shares, the days-to-cover ratio is presently 5.8 days. Approximately 11.8% of the shares of the company are sold short.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on AGEN shares. HC Wainwright reiterated a “neutral” rating and set a $7.00 target price on shares of Agenus in a research note on Friday, November 29th. StockNews.com lowered Agenus from a “hold” rating to a “sell” rating in a report on Monday, August 12th. Finally, B. Riley dropped their price target on shares of Agenus from $42.00 to $18.00 and set a “buy” rating for the company in a research report on Wednesday, August 14th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $10.00.

Agenus Trading Up 5.1 %

NASDAQ AGEN traded up $0.18 on Wednesday, hitting $3.68. 91,904 shares of the company were exchanged, compared to its average volume of 649,177. Agenus has a 1-year low of $2.50 and a 1-year high of $19.69. The firm has a 50 day moving average of $4.09 and a two-hundred day moving average of $7.94. The company has a market cap of $86.33 million, a P/E ratio of -0.31 and a beta of 1.24.

Institutional Trading of Agenus

Hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. lifted its holdings in Agenus by 13.7% in the first quarter. Vanguard Group Inc. now owns 34,401,122 shares of the biotechnology company’s stock valued at $19,953,000 after buying an additional 4,134,232 shares during the period. Geode Capital Management LLC grew its position in shares of Agenus by 7.1% in the 3rd quarter. Geode Capital Management LLC now owns 483,059 shares of the biotechnology company’s stock valued at $2,648,000 after purchasing an additional 32,016 shares during the period. State Street Corp lifted its stake in Agenus by 2.1% in the third quarter. State Street Corp now owns 467,771 shares of the biotechnology company’s stock valued at $2,563,000 after buying an additional 9,731 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Agenus by 52.4% in the first quarter. Price T Rowe Associates Inc. MD now owns 357,915 shares of the biotechnology company’s stock valued at $208,000 after buying an additional 123,058 shares during the period. Finally, Walleye Capital LLC bought a new stake in shares of Agenus during the third quarter worth $1,003,000. 61.46% of the stock is owned by institutional investors.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.